IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc. filed a Form 8-K reporting the results of its annual meeting of stockholders held on June 15, 2023. The company is a Delaware corporation listed on Nasdaq under the symbol INAB and qualifies as an emerging growth company.
Meeting Results and Key Corporate Actions
| Proposal | Result | Vote Details |
|---|---|---|
| Election of Peter Brandt as director through the 2026 annual meeting | Approved | 16,109,637 for; 467,904 withheld; 2,461,297 broker non-votes |
| Election of Travis Whitfill as director through the 2026 annual meeting | Approved | 12,588,240 for; 3,989,301 withheld; 2,461,297 broker non-votes |
| Ratification of the amended and restated 2023 Equity Incentive Plan | Approved | 15,834,351 for; 717,334 against; 25,856 abstained |
| Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal 2023 | Approved | 18,958,459 for; 43,628 against; 36,751 abstained |
Financial Metrics, Liquidity, and Debt
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics.
Material Changes, Outlook, and Risks
The principal reported changes were the election of two directors, approval of the 2023 Equity Incentive Plan, and ratification of the independent accounting firm. The filing provides no new financial guidance, operating outlook, management commentary, contingencies, or unusual items.
Investor Verification Items
- Verify the detailed terms and potential dilution implications of the amended and restated 2023 Equity Incentive Plan in the company’s proxy statement.
- Review the directors’ roles, qualifications, and committee assignments following the election of Peter Brandt and Travis Whitfill.
- Confirm the scope of CohnReznick LLP’s engagement and review subsequent filings for the company’s fiscal 2023 financial results.
- Note that broker non-votes applied to the director elections but were not reported for the other proposals.